Radio-and chemo-sensitizing effects of a new sensitizer, metronidazol amino acidum natrium (CMNa), were studied by the methods of cell surviving fraction (in viiro), tumor growth delay (in vivo) and clinical observati...Radio-and chemo-sensitizing effects of a new sensitizer, metronidazol amino acidum natrium (CMNa), were studied by the methods of cell surviving fraction (in viiro), tumor growth delay (in vivo) and clinical observation. When the hypoxic V79 cells were exposed to γ-ray and CMNa, the cell surviving fraction decreased markedly as compared with radiation alone. The sensitizer enhancement ratio (SER) value was 1. 26-2. 32. When the mice bearing Lewis . B16 melanoma or EMT6 tumors were treated with single dose or fractionated radiation (with or without CMNa) or with antitumor agents (with or without CMNa) the tumor increasing velocity slowed down and the days of tumor growth delay increased significantly when CMNa was given simultaneously.In 96 cases of lung cancer and 80 cases of esophageal cancer patients treated with routine chemotherapy or radiotherapy combined with CMNa, the percentage of CR+PR increased significantly. These results showed that CMNa may be an effective radio- and chemo-sensitizer.展开更多
Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to eva...Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to evaluate its clinical value. Methods: One hundred and twenty cases of advanced NSCLC patients treated by intervention chemotherapy through bronchial artery, collected from 2005 to 2008, were randomly divided into two groups: experimental group (group A), 75 cases, 0.25g CMNa was administered before chemical drugs; control group (group B), 45 cases, chemical drugs only. There were no differences of operation procedures and chemo-regimens between the two groups. After intervention, imaging and clinical data were collected periodically and were processed statistically. Results: The effective rate of group A was higher than that of group B (P < 0.05). Responsive rate (RR) in group A was 61% and it was 38% in group B. There were some side effects in the two groups but there were no statistical differences. Conclusion: Low dose CMNa can enhance chemosensitivity during intervention, which can elevate chemotherapeutical effects on NSCLC. Meanwhile the side effects were not increased. This method is worthy of popularizing.展开更多
目的探讨并分析急性非ST段抬高心肌梗死(NSTEMI)患者经皮冠状动脉介入治疗(PCI)术后血清纤维蛋白原/白蛋白值(FAR)、γ-谷氨酰转肽酶(γ-GGT),N端脑钠肽前体(NT-proBNP)水平对预后的预测价值。方法回顾性分析2020年2月至2023年2月邯郸...目的探讨并分析急性非ST段抬高心肌梗死(NSTEMI)患者经皮冠状动脉介入治疗(PCI)术后血清纤维蛋白原/白蛋白值(FAR)、γ-谷氨酰转肽酶(γ-GGT),N端脑钠肽前体(NT-proBNP)水平对预后的预测价值。方法回顾性分析2020年2月至2023年2月邯郸市中心医院收治的实施PCI的急性NSTEMI患者93例,根据术后30 d主要不良心血管事件(MACE)发生情况将其分为MACE组(n=21)及无MACE组(n=72)。比较术前、术后30 d MACE组及无MACE组血清FAR、γ-GGT、NT-proBNP水平,采用单因素和多因素Logistic回归分析对影响急性NSTEMI患者术后30 d MACE发生的危险因素进行分析,采用受试者操作特征(ROC)曲线分析血清FAR、γ-GGT、NT-proBNP水平对急性NSTEMI患者术后MACE发生的预测价值。结果MACE组年龄为(65.37±3.46)岁;Killip分级为Ⅰ级2例,Ⅱ级3例,Ⅲ级5例,Ⅳ级11例;病变支数双支5例,3支16例;术后30 d血清FAR、γ-GGT、NT-proBNP水平分别为(2.87±0.55)%、(53.27±3.06)U/L、(914.35±84.35)ng/mL。无MACE组的年龄为(58.71±2.86)岁;Killip分级为Ⅰ级32例,Ⅱ级27例,Ⅲ级7例,Ⅳ级6例;病变支数为双支53例,3支19例;术后30 d血清FAR、γ-GGT、NT-proBNP水平分别为(2.12±0.51)%、(44.33±3.35)U/L、(656.82±75.63)ng/mL。MACE组和无MACE组的年龄、Killip分级、病变支数及术后30 d血清FAR、γ-GGT、NT-proBNP水平比较,差异均有统计学意义(P<0.05),两组性别、吸烟史、高血压史、高血脂史、糖尿病史及术前1 d血清FAR、γ-GGT、NT-proBNP水平比较差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,血清FAR、γ-GGT、NT-proBNP升高均为影响急性期NSTEMI患者术后MACE发生的独立危险因素(OR=3.074、2.686、3.340,P均<0.05)。ROC结果显示血清FAR、γ-GGT、NT-proBNP及其联合检测预测急性NSTEMI患者术后MACE发生的曲线下面积(AUC)分别为0.681、0.690、0.733和0.790,联合检测的AUC更高(P<0.05)。结论血清FAR、γ-GGT、NT-proBNP水平升高增加了急性NSTEMI患者PCI术后MACE的发生风险,三者联合检测对患者术后不良预后有一定预测价值。展开更多
文摘Radio-and chemo-sensitizing effects of a new sensitizer, metronidazol amino acidum natrium (CMNa), were studied by the methods of cell surviving fraction (in viiro), tumor growth delay (in vivo) and clinical observation. When the hypoxic V79 cells were exposed to γ-ray and CMNa, the cell surviving fraction decreased markedly as compared with radiation alone. The sensitizer enhancement ratio (SER) value was 1. 26-2. 32. When the mice bearing Lewis . B16 melanoma or EMT6 tumors were treated with single dose or fractionated radiation (with or without CMNa) or with antitumor agents (with or without CMNa) the tumor increasing velocity slowed down and the days of tumor growth delay increased significantly when CMNa was given simultaneously.In 96 cases of lung cancer and 80 cases of esophageal cancer patients treated with routine chemotherapy or radiotherapy combined with CMNa, the percentage of CR+PR increased significantly. These results showed that CMNa may be an effective radio- and chemo-sensitizer.
文摘Objective: The aim of this study was to explore whether low dose Glycididazolum natrium (CMNa) used during intervention for advanced non-small cell lung cancer (NSCLC) patients can enhance chemo-sensitivity and to evaluate its clinical value. Methods: One hundred and twenty cases of advanced NSCLC patients treated by intervention chemotherapy through bronchial artery, collected from 2005 to 2008, were randomly divided into two groups: experimental group (group A), 75 cases, 0.25g CMNa was administered before chemical drugs; control group (group B), 45 cases, chemical drugs only. There were no differences of operation procedures and chemo-regimens between the two groups. After intervention, imaging and clinical data were collected periodically and were processed statistically. Results: The effective rate of group A was higher than that of group B (P < 0.05). Responsive rate (RR) in group A was 61% and it was 38% in group B. There were some side effects in the two groups but there were no statistical differences. Conclusion: Low dose CMNa can enhance chemosensitivity during intervention, which can elevate chemotherapeutical effects on NSCLC. Meanwhile the side effects were not increased. This method is worthy of popularizing.
文摘目的探讨并分析急性非ST段抬高心肌梗死(NSTEMI)患者经皮冠状动脉介入治疗(PCI)术后血清纤维蛋白原/白蛋白值(FAR)、γ-谷氨酰转肽酶(γ-GGT),N端脑钠肽前体(NT-proBNP)水平对预后的预测价值。方法回顾性分析2020年2月至2023年2月邯郸市中心医院收治的实施PCI的急性NSTEMI患者93例,根据术后30 d主要不良心血管事件(MACE)发生情况将其分为MACE组(n=21)及无MACE组(n=72)。比较术前、术后30 d MACE组及无MACE组血清FAR、γ-GGT、NT-proBNP水平,采用单因素和多因素Logistic回归分析对影响急性NSTEMI患者术后30 d MACE发生的危险因素进行分析,采用受试者操作特征(ROC)曲线分析血清FAR、γ-GGT、NT-proBNP水平对急性NSTEMI患者术后MACE发生的预测价值。结果MACE组年龄为(65.37±3.46)岁;Killip分级为Ⅰ级2例,Ⅱ级3例,Ⅲ级5例,Ⅳ级11例;病变支数双支5例,3支16例;术后30 d血清FAR、γ-GGT、NT-proBNP水平分别为(2.87±0.55)%、(53.27±3.06)U/L、(914.35±84.35)ng/mL。无MACE组的年龄为(58.71±2.86)岁;Killip分级为Ⅰ级32例,Ⅱ级27例,Ⅲ级7例,Ⅳ级6例;病变支数为双支53例,3支19例;术后30 d血清FAR、γ-GGT、NT-proBNP水平分别为(2.12±0.51)%、(44.33±3.35)U/L、(656.82±75.63)ng/mL。MACE组和无MACE组的年龄、Killip分级、病变支数及术后30 d血清FAR、γ-GGT、NT-proBNP水平比较,差异均有统计学意义(P<0.05),两组性别、吸烟史、高血压史、高血脂史、糖尿病史及术前1 d血清FAR、γ-GGT、NT-proBNP水平比较差异无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,血清FAR、γ-GGT、NT-proBNP升高均为影响急性期NSTEMI患者术后MACE发生的独立危险因素(OR=3.074、2.686、3.340,P均<0.05)。ROC结果显示血清FAR、γ-GGT、NT-proBNP及其联合检测预测急性NSTEMI患者术后MACE发生的曲线下面积(AUC)分别为0.681、0.690、0.733和0.790,联合检测的AUC更高(P<0.05)。结论血清FAR、γ-GGT、NT-proBNP水平升高增加了急性NSTEMI患者PCI术后MACE的发生风险,三者联合检测对患者术后不良预后有一定预测价值。